



PRESS RELEASE

PAION AG ANNOUNCES CHANGE TO THE SUPERVISORY BOARD

SUPERVISORY BOARD NOMINATES DR. JÖRG SPIEKERKÖTTER AS SUCCESSOR TO DR. FRANZ A. WIRTZ

Aachen, 8 May 2007 – The biopharmaceutical company PAION AG (FSE: PA8) announced today that the current Supervisory Board member and co-founder of PAION, Dr. Franz A. Wirtz, is to leave the Supervisory Board at company's forthcoming annual general meeting on 20 June 2007. Dr. Wirtz will reach the specified age limit this year.

The Supervisory Board thanked Dr. Wirtz for his many years of support and his contributions to the development and growth of the company. At the forthcoming annual general meeting, the Supervisory Board will propose Dr. Jörg Spiekerkötter, currently the Chief Financial Officer at Organon BioSciences N.V., Oss (Netherlands), as Dr. Wirtz's successor.

Dr. Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until September 2006 he was the Chief Financial Officer at Schering AG in Berlin, and before that Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin. Dr. Spiekerkötter, who has a Ph.D. in law, studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany).

"On behalf of the Supervisory Board, I would like to thank Dr. Wirtz for his many years of commitment and support as well as his very active contribution to the success and growth of the company", said Dr. Walter Wenninger, Chairman of the Supervisory Board at PAION AG. "At the same time, we are pleased to be able to nominate Dr. Spiekerkötter as Dr. Wirtz's successor, who also has many years of experience in the pharmaceutical industry".

"With his expertise and contacts, Dr. Wirtz made a significant contribution to the growth of PAION", stated Dr. Wolfgang Söhngen, PAION's CEO. "I would like to thank him once again on a personal level for the time we have spent together, initially at Grünenthal and then since the foundation of PAION." PAION's Chief Medical Officer, Dr. Mariola Söhngen added: "In particular, we would like to thank Dr. Wirtz for his considerable personal investment in the foundation stage which first made the company possible".

Dr. Franz A. Wirtz has supported PAION as its co-founder since 2000, initially on the advisory board at PAION Deutschland GmbH, subsequently as Chairman of the Supervisory Board from 2004 to 2005 and finally as a member of the Supervisory Board at PAION AG.

About PAION

PAION is a biopharmaceutical company based in Aachen, Germany (listed at Frankfurt Stock Exchange, Prime Standard, ISIN DE000A0B65S3). It aims to become a leader in developing and marketing innovative drugs for the treatment of stroke and other thrombotic diseases for which there is a substantial unmet medical need. PAION's activities are focused on the development of the three drugs Desmoteplase, Eneccadin and Solulin. PAION's most advanced drug candidate, Desmoteplase, is partnered with Forest Laboratories, Inc. (USA and Canada) and H. Lundbeck A/S (Europe, Japan, Rest of World). Currently PAION employs more than 80 people.

Contact

Dr. Peer Nils Schröder, Investor Relations / Public Relations
PAION AG
Martinstrasse 10-12
52062 Aachen – Germany
Tel. +49 (0)241 4453 152
E-mail pn.schroeder@paion.de
www.paion.de